This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
I have read with interest a number of Clinical Notes in The Journal in the past 18 months on antibiotic-related respiratory depression (190:421, 1964; 194:298, 1965; 196:181, 1966). Particularly disturbing is the consistency of the theme of reports of apnea induced by the closely related polypeptide antibiotics polymyxin B sulfate and sodium colistimethate.In each of these reports the patients were receiving large or maximally recommended doses of these agents; there was indication of neurologic dysfunction (dysphagia, circumoral paresthesias, blurred vision) hours to days prior to sustained apnea. In spite of symptoms of neurotoxicity, drug administration was continued in unchanged dosages. Two of the patients were azotemic at the inception of therapy (which is in itself an indication for lowered dosage), and the third became azotemic during treatment. In one case, serum concentration of the drug at the time of the apneic episode was
Parisi AF. Antibiotic-Related Respiratory Depression. JAMA. 1966;196(13):1161. doi:10.1001/jama.1966.03100260099044